Kezar Life Sciences Inc. (KZR)
Kezar Life Sciences Statistics
Share Statistics
Kezar Life Sciences has 7.3M shares outstanding. The number of shares has increased by -89.98% in one year.
| Shares Outstanding | 7.3M |
| Shares Change (YoY) | -89.98% |
| Shares Change (QoQ) | -90% |
| Owned by Institutions (%) | 5.16% |
| Shares Floating | 6.22M |
| Failed to Deliver (FTD) Shares | 1.64K |
| FTD / Avg. Volume | 4.23% |
Short Selling Information
The latest short interest is 177.96K, so 2.44% of the outstanding shares have been sold short.
| Short Interest | 177.96K |
| Short % of Shares Out | 2.44% |
| Short % of Float | 2.86% |
| Short Ratio (days to cover) | 0.93 |
Valuation Ratios
The PE ratio is -67.45 and the forward PE ratio is -0.7. Kezar Life Sciences's PEG ratio is -1.52.
| PE Ratio | -67.45 |
| Forward PE | -0.7 |
| PS Ratio | 981.55 |
| Forward PS | 1.3 |
| PB Ratio | 36.63 |
| P/FCF Ratio | -82.33 |
| PEG Ratio | -1.52 |
Enterprise Valuation
Kezar Life Sciences Inc. has an Enterprise Value (EV) of 87.67M.
| EV / Earnings | -0.86 |
| EV / Sales | 12.52 |
| EV / EBITDA | -0.88 |
| EV / EBIT | -0.83 |
| EV / FCF | -1.05 |
Financial Position
The company has a current ratio of 11.66, with a Debt / Equity ratio of 0.1.
| Current Ratio | 11.66 |
| Quick Ratio | 11.66 |
| Debt / Equity | 0.1 |
| Total Debt / Capitalization | 9.17 |
| Cash Flow / Debt | -4.31 |
| Interest Coverage | -67.89 |
Financial Efficiency
Return on equity (ROE) is -0.54% and return on capital (ROIC) is -50.96%.
| Return on Equity (ROE) | -0.54% |
| Return on Assets (ROA) | -0.46% |
| Return on Capital (ROIC) | -50.96% |
| Revenue Per Employee | $120,689.66 |
| Profits Per Employee | $-1,756,379.31 |
| Employee Count | 58 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -94.41% in the last 52 weeks. The beta is 0.19, so Kezar Life Sciences's price volatility has been higher than the market average.
| Beta | 0.19 |
| 52-Week Price Change | -94.41% |
| 50-Day Moving Average | 6.32 |
| 200-Day Moving Average | 34.14 |
| Relative Strength Index (RSI) | 35.82 |
| Average Volume (20 Days) | 38.71K |
Income Statement
In the last 12 months, Kezar Life Sciences had revenue of 7M and earned -101.87M in profits. Earnings per share was -1.4.
| Revenue | 7M |
| Gross Profit | 5.93M |
| Operating Income | -105.24M |
| Net Income | -101.87M |
| EBITDA | -99.25M |
| EBIT | -105.24M |
| Earnings Per Share (EPS) | -1.4 |
Balance Sheet
The company has 35.49M in cash and 18.93M in debt, giving a net cash position of 16.56M.
| Cash & Cash Equivalents | 35.49M |
| Total Debt | 18.93M |
| Net Cash | 16.56M |
| Retained Earnings | -350.76M |
| Total Assets | 164.09M |
| Working Capital | 135.95M |
Cash Flow
In the last 12 months, operating cash flow was -81.64M and capital expenditures -1.81M, giving a free cash flow of -83.45M.
| Operating Cash Flow | -81.64M |
| Capital Expenditures | -1.81M |
| Free Cash Flow | -83.45M |
| FCF Per Share | -1.15 |
Margins
Gross margin is 84.77%, with operating and profit margins of -1.5K% and -1.46K%.
| Gross Margin | 84.77% |
| Operating Margin | -1.5K% |
| Pretax Margin | -1.46K% |
| Profit Margin | -1.46K% |
| EBITDA Margin | -1.42K% |
| EBIT Margin | -1.5K% |
| FCF Margin | -1.19K% |
Dividends & Yields
KZR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -24.56% |
| FCF Yield | -200.56% |
Analyst Forecast
The average price target for KZR is $9, which is 57.9% higher than the current price. The consensus rating is "Hold".
| Price Target | $9 |
| Price Target Difference | 57.9% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Oct 30, 2024. It was a backward split with a ratio of 1:10.
| Last Split Date | Oct 30, 2024 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -3.59 |
| Piotroski F-Score | 2 |